Enovis Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 7,000

Employees

  • Stock Symbol
  • ENOV

Stock Symbol

  • Investments
  • 41

  • Share Price
  • $25.47
  • (As of Friday Closing)

Enovis General Information

Description

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

Contact Information

Website
www.enovis.com
Formerly Known As
Colfax
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Corporate Office
  • 2711 Centerville Road
  • Suite 400
  • Wilmington, DE 19808
  • United States
+1 (302)
Primary Industry
Therapeutic Devices
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • 2711 Centerville Road
  • Suite 400
  • Wilmington, DE 19808
  • United States
+1 (302)

Enovis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enovis Stock Performance

As of 20-Nov-2026, Enovis’s stock price is $25.47. Its current market cap is $1.47B with 57.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.47 $26.23 $16.70 - $31.66 $1.47B 57.7M 1.69M -$9.22

Enovis Financials Summary

As of 30-Sep-2026, Enovis has a trailing 12-month revenue of $2.31B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,412,205 2,934,165 3,833,709 3,493,431
Revenue 2,306,416 2,248,049 2,107,623 1,707,197
EBITDA (174,672) (830,217) (481,028) 169,730
Net Income (527,404) (1,184,440) (825,494) (33,261)
Total Assets 3,735,544 3,834,737 4,718,777 4,509,334
Total Debt 1,342,530 1,379,535 1,404,301 536,416
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Enovis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Enovis‘s full profile, request access.

Request a free trial

Enovis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, reha
Therapeutic Devices
Wilmington, DE
7,000 As of 2026

Reykjavik, Iceland
 

Warsaw, IN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enovis Competitors (2)

One of Enovis’s 2 competitors is Embla Medical, a Corporation company based in Reykjavik, Iceland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Embla Medical Corporation Reykjavik, Iceland
Zimmer Biomet Holdings Corporation Warsaw, IN
You’re viewing 2 of 2 competitors. Get the full list »

Enovis Patents

Enovis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260207342-A1 Total ankle replacement with gradient porous structure Pending 17-Jan-2025
WO-2026156205-A1 Total ankle replacement with gradient porous structure Pending 17-Jan-2025
US-20260207341-A1 Total ankle replacement with variable constraint articulating surfaces Pending 17-Jan-2025
WO-2026156204-A1 Total ankle replacement with variable constraint articulating surfaces Pending 17-Jan-2025
WO-2026050360-A1 A stem system for use in total ankle replacement surgery and methods of using the same Pending 30-Aug-2024 A61F2/4202
To view Enovis’s complete patent history, request access »

Enovis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enovis Investments & Acquisitions (41)

Enovis’s most recent deal was a Merger/Acquisition with eCential Robotics for . The deal was made on 01-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
eCential Robotics 01-Sep-2026 Merger/Acquisition Diagnostic Equipment
ManaMed 31-Jan-2025 Corporate Asset Purchase Therapeutic Devices
Limacorporate 03-Jan-2024 Merger/Acquisition Therapeutic Devices
Precision AI Australia 05-Oct-2023 Merger/Acquisition Therapeutic Devices
SEAL External Fixation 20-Jul-2023 Merger/Acquisition Therapeutic Devices
You’re viewing 5 of 41 investments and acquisitions. Get the full list »

Enovis ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

30.24 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view Enovis’s complete esg history, request access »

Enovis Exits (2)

Enovis’s most recent exit was on 09-Jul-2013 from Clarus Fluid Intelligence. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Clarus Fluid Intelligence 09-Jul-2013 Completed
COT-Puritech 06-Dec-2011 Merger/Acquisition Completed
To view Enovis’s complete exits history, request access »

Enovis Affiliates

Subsidiaries (20)

Name Industry Location Year Founded
Precision AI Australia Fortitude Valley, Australia 2019
Surgi-Care Sales South Burlington, VT 2019
Soldex Holdings I Annapolis Junction, MD 2019
Howden Construction Services Annapolis Junction, MD 2017
Clfx Sub Holding Annapolis Junction, MD 2017
You’re viewing 5 of 20 affiliates. Get the full list.  »

Enovis FAQs

  • When was Enovis founded?

    Enovis was founded in 1995.

  • Where is Enovis headquartered?

    Enovis is headquartered in Wilmington, DE.

  • What is the size of Enovis?

    Enovis has 7,000 total employees.

  • What industry is Enovis in?

    Enovis’s primary industry is Therapeutic Devices.

  • Is Enovis a private or public company?

    Enovis is a Public company.

  • What is Enovis’s stock symbol?

    The ticker symbol for Enovis is ENOV.

  • What is the current stock price of Enovis?

    As of 20-Nov-2026 the stock price of Enovis is $25.47.

  • What is the current market cap of Enovis?

    The current market capitalization of Enovis is $1.47B.

  • What is Enovis’s current revenue?

    The trailing twelve month revenue for Enovis is $2.31B.

  • Who are Enovis’s competitors?

    Embla Medical and Zimmer Biomet Holdings are competitors of Enovis.

  • What is Enovis’s annual earnings per share (EPS)?

    Enovis’s EPS for 12 months was -$9.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process